Algae supplement and treatment method

• US 20080124318A1
• Filed: 05/03/2007
• Published: 05/29/2008
• Est. Priority Date: 11/28/2006
• Status: Abandoned Application

• Current Assignee: Jerold Lisson
• Original Assignee: Jerold Lisson
• Inventors: Lisson, Jerold
• Application Number:
  US11/800,018
• Publication Number:
  US 20080124318A1
• Time in Patent Office: Days
• US Class Current: 424/130.1
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 35/748 Cyanobacteria, i.e. blue-green bacteria or blue-green algae, e.g. spirulina algae, microalgae or microphytes A61K36/02
• CPC Class Codes: A61K 36/05 Chlorophycota or chlorophyta (green algae), e.g. Chlorella
• CPC Class Codes: A61P 39/00 General protective or antinoxious agents

Abstract

This invention relates to a method and composition for enhancing pluripotent cell production, longevity and homing to injured or diseased sites, and more specifically, by administration of a therapeutic dosage of cyanobacteria and green algae. The increased concentration of pluripotent cells within the circulatory system of animals is effected by the transient increase of pluripotent cell production and the concommitant extension of the pluripotent cell life cycle.

Claims

1. A method for enhancing health and disease control in a subject, comprising:

administering to a subject a composition comprising a therapeutic dosage comprising green algae and cyanobacteria.

2. The method according to claim 1, where said subject is a mammal.

3. The method according to claim 2, where said subject is a human.

4. The method according to claim 3, wherein from about 1 gram to about 10 grams of said green algae is administered.

5. The method according to claim 4, wherein said green bacteria is administered as whole cells.

6. The method according to claim 3, wherein from about 2 to about 10 grams of said cyanobacteria is administered.

7. The method according to claim 6, wherein from about 1 gram to about 10 grams of said green algae is administered.

8. The method according to claim 6, wherein said cyanobacteria is administered as whole cells.

9. The method according to claim 8, wherein said green bacteria is administered as whole cells, wherein said green bacteria and said cyanobacteria provide increased trace nutrient concentrations.

10. The method according to claim 6, wherein said cyanobacteria enhances the concentration of pluripotent cells.

11. The method according to claim 10, wherein said concentration of pluripotent cells are disposed in an enhanced concentration site.

12. The method according to claim 11, wherein said enhanced concentration site comprises a site selected from the group consisting of a circulatory system, a diseased site, and an injured site.

13. The method according to claim 4, wherein said green algae comprises from about 0.01 to about 50.0 weight percent of antioxidants.

14. The method according to claim 13, wherein said green algae comprises from about 0.01 to about 1.0 weight percent of antioxidants.

15. The method according to claim 14, wherein said green algae comprises from about 0.01 to about 0.05 weight percent of antioxidants.

16. The method according to claim 13, wherein said antioxidants preserve said pluripotent cells.

17. The method according to claim 7, wherein said composition comprises a form selected from the group consisting of a dry powder, liquid suspension and tablet.

18. A method for enhancing the production of pluripotent cells and increasing the longevity of said pluripotent cells in a subject, comprising:

administering to a human a composition comprising a therapeutic dosage comprising green algae and cyanobacteria, thereby enhancing pluripotent cell concentration in a subject.

19. The method according to claim 18, wherein from about 2 to about 10 grams per day of said cyanobacteria is administered.

20. The method according to claim 18, wherein from about 1 gram to about 10 grams per day of said green algae is administered.

21. The method according to claim 18, wherein said composition comprises a form selected from the group consisting of a dry powder, liquid suspension and tablet.

22. The method according to claim 19, wherein said cyanobacteria enhances the concentration of pluripotent cells.

23. The method according to claim 20, wherein said green algae comprises from about 0.01 to about 10.0 weight percent of antioxidants.

24. The method according to claim 23, wherein said green algae comprises from about 0.01 to about 1.0 weight percent of antioxidants.

25. The method according to claim 23, wherein said antioxidants preserve said pluripotent cells.

26. The method according to claim 18, wherein said composition comprises about 5 grams of Aphanizomenon flos-aquae, from about 4 grams to about 5 grams of Spirulina, and about 2 grams of Chlorella.

27. The method according to claim 20, wherein said green algae comprises from about 0.01 to about 50.0 weight percent of mucopolysaccharides.

28. The method according to claim 27, wherein said mucopolysaccharides bind with environmental toxins.

29. A composition for enhancing health and disease control in humans, comprising:

a therapeutic dosage comprising green algae and cyanobacteria.

30. The composition of claim 29, wherein said green algae comprises a green algae selected from the group consisting of Haematoccus pluvialis, Chlorella vulgaris, Chlorella pyrenoidosa, Dunaliella salina or a combination thereof

31. The composition of claim 29, wherein said cyanobacteria comprises a cyanobacteria selected from the group consisting of Aphanizomenon flos-aquae, Spirulina pacifica, Spirulina plantesis or a combination thereof.

32. The composition of claim 29, wherein said therapeutic dosage comprises from about 30 to about 70 weight percent of said green algae.

33. The composition of claim 29, wherein said therapeutic dosage comprises from about 30 to about 70 weight percent of said cyanobacteria.

34. The composition of claim 29, wherein said composition further comprises pharmaceutically acceptable carriers.

35. The composition of claim 29, wherein said composition further comprises a palatability enhancer.

36. The composition of claim 29, wherein said composition comprises a form selected from the group consisting of a dry powder, liquid suspension and tablet.

37. The composition of claim 32, wherein said green algae comprises from about 0.01 to about 10.0 weight percent of antioxidants.

38. The composition of claim 37, wherein said green algae comprises from about 0.01 to about 1.0 weight percent of antioxidants.

39. The composition of claim 37, wherein said 0.01 to about 10.0 weight per cent of antioxidants comprises at least one antioxidant selected from the group consisting of zeaxanthin 9-cis-beta-carotene and beta-CDS.

40. The composition of claim 37, wherein said composition comprises from about 2 milligrams to about 3.75 milligrams of astaxanthin.

41. The composition of claim 37, wherein said composition comprises about 5 milligrams of astaxanthin.

42. The composition of claim 39, wherein said composition comprises from about 500 micrograms to about 1000 micrograms of zeaxanthin.

43. The composition of claim 42, wherein said composition comprises about 800 micrograms of zeaxanthin.

44. The composition of claim 39, wherein said composition comprises from about 10 milligrams to about 20 milligrams of 9-cis-beta-carotene.

45. The composition of claim 44, wherein said composition comprises about 15 milligrams of 9-cis-beta-carotene.

46. The composition of claim 39, wherein said composition comprises from about 10 milligrams to about 20 milligrams of beta-CDS.

47. The composition of claim 46, wherein said composition comprises about 15 milligrams of beta-CDS.

48. The composition of claim 29, wherein said composition comprises about 5 grams of Aphanizomenon flos-aquae, about 4 grams to about 5 grams of Spirulina pacifica, and about 2 grams of Chlorella vulgaris.

49. The composition of claim 29, wherein said composition further comprises an immunoglobulin.

50. The composition of claim 49, wherein said immunoglobulin comprises beta-CDS.

51. The composition of claim 29, wherein said composition further comprises an L-selectin ligand.

52. The composition of claim 29, wherein said composition comprises Haematoccus pluvialis, Aphanizomenon flos-aquae and Dunaliella salina.

53. The composition of claim 52, wherein said composition further comprises Chlorella vulgaris and Spirulina pacifica.